Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Total Liabilities (2016 - 2025)

Aytu Biopharma (AYTU) has disclosed Total Liabilities for 14 consecutive years, with $107.8 million as the latest value for Q4 2025.

  • On a quarterly basis, Total Liabilities rose 26.14% to $107.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $107.8 million, a 26.14% increase, with the full-year FY2025 number at $105.2 million, up 16.41% from a year prior.
  • Total Liabilities was $107.8 million for Q4 2025 at Aytu Biopharma, up from $101.8 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $128.1 million in Q2 2021 to a low of $85.5 million in Q4 2024.
  • A 5-year average of $101.4 million and a median of $100.7 million in 2023 define the central range for Total Liabilities.
  • Peak YoY movement for Total Liabilities: surged 131.5% in 2021, then dropped 27.15% in 2022.
  • Aytu Biopharma's Total Liabilities stood at $118.3 million in 2021, then dropped by 19.16% to $95.6 million in 2022, then rose by 2.9% to $98.4 million in 2023, then dropped by 13.14% to $85.5 million in 2024, then rose by 26.14% to $107.8 million in 2025.
  • Per Business Quant, the three most recent readings for AYTU's Total Liabilities are $107.8 million (Q4 2025), $101.8 million (Q3 2025), and $105.2 million (Q2 2025).